Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Deborah M. Stephens et al.|New England Journal of Medicine|2015Cited by 890
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Peter Hillmen et al.|Journal of Clinical Oncology|2021Cited by 630
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 studyToby A. Eyre, Peter Hillmen, Anna Schuh et al.|The Lancet Haematology|2021Cited by 60
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated TranscriptionMelanie M. Frigault, Ahmed Hamdy|Cancer Research Communications|2023Cited by 16